Physician profile
Marshall P Mcmillan
NPI 1093701666
$2,376.32
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $506 · 2021: $1,148 · 2022: $382 · 2024: $47.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $639.87 | 2019-2024 | Wegovy |
| Amgen INC. | $358.78 | 2019-2022 | |
| Abbvie INC. | $248.97 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $180.68 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $146.41 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.08 | 2019-2022 | |
| Abbott Laboratories | $102.69 | 2019-2022 | |
| Amarin Pharma, INC. | $87.40 | 2020-2021 | |
| Lilly USA, LLC | $83.06 | 2020-2021 | |
| Allergan, INC. | $56.02 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.59 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $42.75 | 2021 | |
| Sanofi-Aventis U.S. LLC | $37.24 | 2020-2021 | |
| Astellas Pharma US INC | $33.14 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $27.99 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $23.94 | 2022 | |
| Pfizer INC. | $23.22 | 2019-2021 | |
| Clarus Therapeutics INC. | $16.95 | 2021 | |
| Sanofi Pasteur INC. | $15.80 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.47 | 2019 | |
| Antares Pharma, INC. | $14.36 | 2022 | |
| Hologic Sales and Service, LLC | $13.92 | 2021 | |
| Glaxosmithkline, LLC. | $13.76 | 2020 | |
| Merck Sharp & Dohme LLC | $13.17 | 2021 | |
| Cranial Technologies, INC | $12.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Mcmillan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.